Sustained Remission after Rituximab-containing  Chemotherapy for Intravascular Large B-cell Lymphoma

Kazuyuki Shimada; Hiroshi Kosugi; Hiroto Narimatsu; Satoko Shimada; Tatsuya Suzuki; Masafumi Ito; Tomohiro Kinoshita; Naoyoshi Mori; Tomoki Naoe

doi:10.3960/jslrt.48.25

Case Study

Sustained Remission after Rituximab-containing
Chemotherapy for Intravascular Large B-cell Lymphoma

Kazuyuki Shimada, Hiroshi Kosugi, Hiroto Narimatsu, Satoko Shimada, Tatsuya Suzuki, Masafumi Ito, Tomohiro Kinoshita, Naoyoshi Mori, Tomoki Naoe

Author information

Kazuyuki Shimada
Department of Hematology, Ogaki Municipal Hospital
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Hiroshi Kosugi
Department of Hematology, Ogaki Municipal Hospital
Hiroto Narimatsu
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Satoko Shimada
Department of Pathology of Biological Response, Nagoya University Graduate School of Medicine
Tatsuya Suzuki
Department of Hematology, Ogaki Municipal Hospital
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Masafumi Ito
Department of Pathology, Japanese Red Cross, Nagoya First Hospital
Tomohiro Kinoshita
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Naoyoshi Mori
Department of Pathology of Biological Response, Nagoya University Graduate School of Medicine
Tomoki Naoe
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

Keywords: intravascular large B-cell lymphoma, rituximab, combination chemotherapy

JOURNAL FREE ACCESS

2008 Volume 48 Issue 1 Pages 25-28

DOI https://doi.org/10.3960/jslrt.48.25

Details

Abstract

Intravascular large B-cell lymphoma (IVL) is rare aggressive disseminated lymphoma associated with poor outcomes. Rituximab is a novel molecular agent that can reportedly improve outcomes for patients with diffuse large B-cell lymphoma. However, the safety and efficacy of rituximab in patients with IVL are unclear. A 76-year-old woman was hospitalized due to altered consciousness, fever and respiratory abnormalities. Definitive diagnosis of IVL was obtained following repeated biopsies of bone marrow. The patient received chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP), and achieved complete remission after 3 courses of treatment. She has remained in complete remission for over 3 years after diagnosis. This report suggests that rituximab-containing regimens could be safe and effective for elderly patients with IVL. [J Clin Exp Hematopathol 48(1) : 25-28, 2008]

Corresponding author

Register with J-STAGE for free!